Monique Tan

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

The clinician’s guide to prevention and treatment of osteoporosis

Clinician’s Guide to Prevention and Treatment of Osteoporosis

UK clinical guideline for the prevention and treatment of osteoporosis

American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary

Compounds enhanced in a mass spectrometric profile of smokers' exhaled breath versus non-smokers as determined in a pilot study using PTR-MS

Osteoporosis

Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

Benefits and Risks of Bisphosphonate Therapy for Osteoporosis

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?

Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?

Epidemiology and pathogenesis of osteonecrosis of the jaw

Using Osteoporosis Therapies in Combination

Management of severe osteoporosis

2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway

2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association

American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016

Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration

Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Formaldehyde in the Indoor Environment

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis

Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective

Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis

Addressing unmeasured confounding in comparative observational research

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update

Postmenopausal Osteoporosis

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

Salt Reduction to Prevent Hypertension and Cardiovascular Disease

Breath carbon monoxide as an indication of smoking habit in the military setting.

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)